BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 29509538)

  • 21. Clinical outcome of elderly patients (≥ 70 years) with esophageal cancer undergoing definitive or neoadjuvant radio(chemo)therapy: a retrospective single center analysis.
    Walter F; Böckle D; Schmidt-Hegemann NS; Köpple R; Gerum S; Boeck S; Angele M; Belka C; Roeder F
    Radiat Oncol; 2018 May; 13(1):93. PubMed ID: 29769143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
    Zanoni A; Verlato G; Giacopuzzi S; Weindelmayer J; Casella F; Pasini F; Zhao E; de Manzoni G
    Ann Surg Oncol; 2013 Jun; 20(6):1993-9. PubMed ID: 23274533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy.
    Matsuda S; Tsubosa Y; Niihara M; Sato H; Takebayashi K; Kawamorita K; Mori K; Tsushima T; Yokota T; Ogawa H; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2015; 22(6):1866-73. PubMed ID: 25564176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy.
    Boggs DH; Hanna A; Burrows W; Horiba N; Suntharalingam M
    J Gastrointest Cancer; 2015 Jun; 46(2):131-7. PubMed ID: 25759174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre.
    Saigí M; Oliva M; Aliste L; Calvo M; Hormigo G; Serra Ò; Boladeras A; Farran L; Robles J; Creus G; Paúles MJ; Gornals JB; de Lama E; Borràs JM; Sala N; Galán M
    PLoS One; 2017; 12(9):e0184737. PubMed ID: 28931046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of response evaluation for resectable esophageal adenocarcinoma - a retrospective cohort study.
    Bachmann R; Bachmann J; Hungbauer A; Schmehl J; Sitzmann G; Königsrainer A; Ladurner R
    Int J Surg; 2014 Oct; 12(10):1025-30. PubMed ID: 25192805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonsurgical management of esophageal adenocarcinoma.
    Gujral DM; Hawkins MA; Leonulli BG; Ashley S; Chau I; Cunningham D; Tait D
    Clin Colorectal Cancer; 2011 Sep; 10(3):165-70. PubMed ID: 21855037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radio(chemo)therapy for locally advanced squamous cell carcinoma of the esophagus: long-term outcome.
    Ordu AD; Nieder C; Geinitz H; Kup PG; Deymann LF; Scherer V; Combs SE; Fakhrian K
    Strahlenther Onkol; 2015 Feb; 191(2):153-60. PubMed ID: 25404062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma.
    Bekkar S; Gronnier C; Messager M; Robb WB; Piessen G; Mariette C;
    Ann Thorac Surg; 2014 Jan; 97(1):303-10. PubMed ID: 24200394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is pathological complete response after a trimodality therapy, a predictive factor of long-term survival in locally-advanced esophageal cancer? Results of a retrospective monocentric study.
    Francoual J; Lebreton G; Bazille C; Galais MP; Dupont B; Alves A; Lubrano J; Morello R; Menahem B
    J Visc Surg; 2018 Oct; 155(5):365-374. PubMed ID: 29501383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The multimodality therapy of advanced inoperable esophageal carcinoma. A retrospective analysis].
    Mücke R; Ziegler PG; Libera T; Klautke G; Fietkau R
    Strahlenther Onkol; 2000 Aug; 176(8):350-5. PubMed ID: 10987017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma.
    Bates BA; Detterbeck FC; Bernard SA; Qaqish BF; Tepper JE
    J Clin Oncol; 1996 Jan; 14(1):156-63. PubMed ID: 8558191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy.
    Chidel MA; Rice TW; Adelstein DJ; Kupelian PA; Suh JH; Becker M
    Radiology; 1999 Oct; 213(1):67-72. PubMed ID: 10540642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Curative treatment for esophageal cancer: Vancouver Island Cancer Centre experience from 1993 to 1998.
    Wilson KS; Wilson AG; Dewar GJ
    Can J Gastroenterol; 2002 Jun; 16(6):361-8. PubMed ID: 12096299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.
    Watkins JM; Zauls AJ; Kearney PL; Shirai K; Ruppert BN; Harper JL; Sherman CA; Aguero EG; Reed CE; Sharma AK
    Jpn J Clin Oncol; 2011 Mar; 41(3):334-42. PubMed ID: 21084436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of Unresectable T4b Esophageal Cancer: Practice Patterns and Outcomes From the National Cancer Data Base.
    Cushman TR; Shaaban SG; Moreno AC; Lin C; Verma V
    Am J Clin Oncol; 2019 Feb; 42(2):154-159. PubMed ID: 30499838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
    Mantziari S; Gronnier C; Renaud F; Duhamel A; Théreaux J; Brigand C; Carrère N; Lefevre JH; Pasquer A; Demartines N; Collet D; Meunier B; Mariette C;
    Ann Surg; 2017 Nov; 266(5):805-813. PubMed ID: 28742698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
    Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Radiochemotherapy for esophageal cancer: which nodes should be irradiated?].
    Créhange G; Quivrin M; Vulquin N; Serre AA; Maingon P
    Cancer Radiother; 2014 Oct; 18(5-6):577-82. PubMed ID: 25201634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.
    Lutz MP; Zalcberg JR; Ducreux M; Ajani JA; Allum W; Aust D; Bang YJ; Cascinu S; Hölscher A; Jankowski J; Jansen EP; Kisslich R; Lordick F; Mariette C; Moehler M; Oyama T; Roth A; Rueschoff J; Ruhstaller T; Seruca R; Stahl M; Sterzing F; van Cutsem E; van der Gaast A; van Lanschot J; Ychou M; Otto F;
    Eur J Cancer; 2012 Nov; 48(16):2941-53. PubMed ID: 22921186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.